Aurinia Pharmaceuticals Inc. (AUPH) Cash Flow Statement

The 2025Q4 net income of $210.8M was supported by only $44.6M of operating cash flow, which suggests the headline profit was driven by a non-cash or non-operating item rather than core collections. Conversely, the 2026Q3 quarter showed operating cash flow exceeding net income, which may indicate working capital inflows or non-cash charges flattering the conversion ratio. Investors should monitor whether the conversion ratio normalizes toward a stable band, as the current spread warrants further investigation before treating reported earnings as a reliable base.

Capital expenditure remained negligible throughout the period, so free cash flow closely tracks operating cash flow and is therefore sensitive to working capital timing and collection patterns. The 2025Q1 trough and the sustained 40% to 60% margins in subsequent quarters suggest cash generation is currently strong but not yet demonstrated as durable across a full cycle. Investors may wish to weigh the trailing quarterly average more heavily than any single quarter.

The magnitude of these swings relative to quarterly operating cash flow suggests that a meaningful share of reported cash generation depends on timing rather than steady-state earnings power. Reversals such as the $12.9M outflow in 2026Q1 followed by the $6.7M inflow in 2025Q4 point to lumpy collections or payment cycles. This pattern may indicate that trailing multi-quarter cash flow is a more reliable indicator than any individual period.

The absence of dividends alongside episodic repurchases suggests management has prioritized flexibility over a predictable shareholder distribution policy. The large 2026Q2 buyback, relative to that quarter's $85.1M operating cash flow, implies a substantial share of cash generation was returned in a single period. Whether this pattern is sustainable or opportunistic cannot be determined from the supplied data alone and warrants further investigation.